Jennifer S Albrecht1, Emerson M Wickwire2, Aparna Vadlamani3, Steven M Scharf4, Sarah E Tom5. 1. Department of Epidemiology and Public Health (JSA, AV), University of Maryland School of Medicine, Baltimore. Electronic address: jalbrecht@som.umaryland.edu. 2. the Department of Psychiatry (EMW), University of Maryland School of Medicine, Baltimore; the Sleep Disorders Center (EMW, SMS), Division of Pulmonary and Critical Care Medicine, Department of Medicine, University of Maryland School of Medicine, Baltimore. 3. Department of Epidemiology and Public Health (JSA, AV), University of Maryland School of Medicine, Baltimore. 4. the Sleep Disorders Center (EMW, SMS), Division of Pulmonary and Critical Care Medicine, Department of Medicine, University of Maryland School of Medicine, Baltimore. 5. Department of Neurology (SET), Columbia University, New York.
Abstract
OBJECTIVE: Insomnia is an important clinical problem affecting the elderly. We examined trends in insomnia diagnosis and treatment among Medicare beneficiaries over an eight-year period. METHODS: This was a time-series analysis of Medicare administrative data for years 2006-2013. Insomnia was defined as the presence of at least one claim containing International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), code 307.41, 307.42, 307.49, 327.00, 327.01, 327.09, 780.52, or V69.4 in any given year. Insomnia medications were identified by searching the Part D prescription drug files in each year for barbiturates, benzodiazepines, chloral hydrate, hydroxyzine, nonbenzodiazepine sedative hypnotics, and sedating antidepressants. RESULTS: Prevalence of physician-assigned insomnia diagnoses increased from 3.9% in 2006 to 6.2% in 2013. Prevalence of any insomnia medication use ranged from 21.0% in 2006 to 29.6% in 2013 but remained steady. A sharp increase in use of benzodiazepines from 2012-2013 (1.1% to 17.6%) drove up total insomnia medication use for 2013. Prevalence of both insomnia diagnosis and medication use ranged from 3.5% in 2006 to 5.5% in 2013, while prevalence of either insomnia diagnosis or medication use ranged from 22.7% in 2006 to 31.0% in 2013. CONCLUSION: In this large national analysis of Medicare beneficiaries, prevalence of physician-assigned insomnia diagnoses was low but increased over time. Prevalence of insomnia medication use was up to four-times higher than insomnia diagnoses and remained steady over time. Notably, prevalence of benzodiazepine use increased dramatically from 2012-2013 after these medications were included in the Medicare Part D formulary.
OBJECTIVE:Insomnia is an important clinical problem affecting the elderly. We examined trends in insomnia diagnosis and treatment among Medicare beneficiaries over an eight-year period. METHODS: This was a time-series analysis of Medicare administrative data for years 2006-2013. Insomnia was defined as the presence of at least one claim containing International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), code 307.41, 307.42, 307.49, 327.00, 327.01, 327.09, 780.52, or V69.4 in any given year. Insomnia medications were identified by searching the Part D prescription drug files in each year for barbiturates, benzodiazepines, chloral hydrate, hydroxyzine, nonbenzodiazepine sedative hypnotics, and sedating antidepressants. RESULTS: Prevalence of physician-assigned insomnia diagnoses increased from 3.9% in 2006 to 6.2% in 2013. Prevalence of any insomnia medication use ranged from 21.0% in 2006 to 29.6% in 2013 but remained steady. A sharp increase in use of benzodiazepines from 2012-2013 (1.1% to 17.6%) drove up total insomnia medication use for 2013. Prevalence of both insomnia diagnosis and medication use ranged from 3.5% in 2006 to 5.5% in 2013, while prevalence of either insomnia diagnosis or medication use ranged from 22.7% in 2006 to 31.0% in 2013. CONCLUSION: In this large national analysis of Medicare beneficiaries, prevalence of physician-assigned insomnia diagnoses was low but increased over time. Prevalence of insomnia medication use was up to four-times higher than insomnia diagnoses and remained steady over time. Notably, prevalence of benzodiazepine use increased dramatically from 2012-2013 after these medications were included in the Medicare Part D formulary.
Authors: Donovan T Maust; Frederic C Blow; Ilse R Wiechers; Helen C Kales; Steven C Marcus Journal: J Clin Psychiatry Date: 2017-04 Impact factor: 4.384
Authors: Earl S Ford; Anne G Wheaton; Timothy J Cunningham; Wayne H Giles; Daniel P Chapman; Janet B Croft Journal: Sleep Date: 2014-08-01 Impact factor: 5.849
Authors: Emerson M Wickwire; Aparna Vadlamani; Sarah E Tom; Abree M Johnson; Steven M Scharf; Jennifer S Albrecht Journal: Sleep Date: 2020-01-13 Impact factor: 5.849
Authors: S Justin Thomas; Swati Sakhuja; Lisandro D Colantonio; Mei Li; Paul Muntner; Kristi Reynolds; C Barrett Bowling Journal: Sleep Date: 2022-03-11 Impact factor: 6.313
Authors: Judith Sys; Simon Van Cleynenbreugel; Mieke Deschodt; Lorenz Van der Linden; Jos Tournoy Journal: Eur J Clin Pharmacol Date: 2019-12-14 Impact factor: 2.953
Authors: Emerson M Wickwire; Sarah E Tom; Aparna Vadlamani; Montserrat Diaz-Abad; Liesl M Cooper; Abree M Johnson; Steven M Scharf; Jennifer S Albrecht Journal: J Clin Sleep Med Date: 2019-12-05 Impact factor: 4.062
Authors: Zachary A Haynes; Jacob F Collen; Eduard A Poltavskiy; Lauren E Walker; Jud Janak; Jeffrey T Howard; J Kent Werner; Emerson M Wickwire; Aaron B Holley; Lee Ann Zarzabal; Alan Sim; Adi Gundlapalli; Ian J Stewart Journal: J Clin Sleep Med Date: 2021-09-01 Impact factor: 4.324